NCT02588170 is a Phase 3 clinical trial of Surufatinib in Neuroendocrine Tumors, sponsored by Hutchison Medipharma Limited.

Who is sponsoring NCT02588170?

NCT02588170 is sponsored by Hutchison Medipharma Limited.

What drugs are being tested in NCT02588170?

Interventions in NCT02588170: Surufatinib, Placebo.

What condition does NCT02588170 study?

NCT02588170 studies Neuroendocrine Tumors.

Is NCT02588170 still recruiting?

NCT02588170 is currently completed. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT02588170

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Completed Phase 3 Last updated 30 March 2023

What this trial tests

Phase 3 trial testing Surufatinib in Neuroendocrine Tumors in 219 participants. Completed in 7 July 2022.

Timeline

7 December 2015

Primary endpoint
31 March 2019

7 July 2022

Quick facts

Lead sponsor	Hutchison Medipharma Limited
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	219
Start date	7 December 2015
Primary completion	31 March 2019
Estimated completion	7 July 2022
Sites	5 locations across China

Drugs / interventions tested

Surufatinib — full drug profile →
Placebo

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

Hutchison Medipharma Limited — full company profile →

Who can join

18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, et al · · 2021 · cited 1003× · PMID 34054126 · DOI 10.1038/s41392-021-00572-w
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Patel SA, Nilsson MB, Le X, Cascone T, et al · · 2023 · cited 321× · PMID 35969170 · DOI 10.1158/1078-0432.ccr-22-1366
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
Qin S, Li A, Yi M, Yu S, et al · · 2019 · cited 221× · PMID 30866992 · DOI 10.1186/s13045-019-0718-5
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J, Shen L, Zhou Z, Li J, et al · · 2020 · cited 153× · PMID 32966811 · DOI 10.1016/s1470-2045(20)30496-4
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, et al · · 2024 · cited 133× · PMID 39138146 · DOI 10.1038/s41392-024-01899-w
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.
Hofland J, Kaltsas G, de Herder WW. · · 2020 · cited 121× · PMID 31555796 · DOI 10.1210/endrev/bnz004
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
Targeting FGFR for cancer therapy.
Zhang P, Yue L, Leng Q, Chang C, et al · · 2024 · cited 64× · PMID 38831455 · DOI 10.1186/s13045-024-01558-1

Verify or expand the search:

Other trials of Surufatinib

Trials testing the same drug.

NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors · Phase 2 · recruiting
NCT07086456 — Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal · Phase 2 · recruiting
NCT06531291 — Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Ne · Phase 2 · not yet recruiting

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Hutchison Medipharma Limited trials

Trials by the same sponsor.

NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02588170 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02588170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing